Skip to main content
. 2022 Sep 24;14(19):3978. doi: 10.3390/nu14193978

Figure 8.

Figure 8

Mon suppresses the activation of Akt/GSK-3β pathway in LPS-treated osteoclast derived from BMMs and the molecular docking studies (n = 3). (A(a)) Representative imagines of Western blot for the expression of P-GSK-3β, GSK-3β, P-AKT and AKT in osteoclast; (A(b,c)) quantitative analysis of P-GSK-3β/GSK-3β and P-AKT/AKT, respectively. * p < 0.05, ** p < 0.01 compared with LPS group at corresponding time point. (B(a)) SC79, an Agonist of AKT reversed the regulatory effects of Mon on AKT pathway in osteoclast as showed by expression of key proteins in representative images of Western blot; (B(b)) quantitative analysis of P-AKT/AKT. * p < 0.05 vs. ctrl group, # p < 0.05 compared with SC79 group. (C) predicted binding mode of Mon with Akt. The data are expressed as means ± SD.